For a deeper look at what GLP-1 approval actually required, Meto's clinical overview of GLP-1 drugs provides useful context as does our recent piece on Foundayo (orforglipron), the first oral GLP-1 to reach approval
Who Should Avoid It Not for those with personal/family history of thyroid cancer (MTC), MEN2 syndrome, active pancreatitis, or severe gastroparesis
Are there rare but serious adverse events that only appear across thousands of patients
GP Lead BSc (Hons), MBBS, MRCGP, PGDip (SEM), DFSEM Dr
Looking forward, the methodological and computational framework outlined here may be applicable to a clinical setting for example in cancer, where sensitive phosphoproteomics profiling of individual patient tumors may aid precision medicine in the future
Lu, N., Jun, J